Biocon Limited reports Q1 FY27 earnings: Revenue from Operations stands at 4,336 ₹ Cr as Biosimilars lead growth

Biocon Limited reports Q1 FY27 earnings: Revenue from Operations stands at 4,336 ₹ Cr as Biosimilars lead growth​

Biocon Limited has released its first-quarter financial results for Fiscal Year 2027. The company reported a Total Revenue of 4,391 ₹ Cr and Net Profit (Reported) of 141 ₹ Cr, showing significant growth in the net profit despite mixed segment performance.

The Q1 FY27 Financial Highlights reveal a varied picture across operations, with the Biosimilars segment driving profitability.

Financial Overview (Q1 FY27 vs Prior Periods)​

Total Revenue for Biocon Limited stood at 4,391 ₹ Cr in Q1 FY27, compared to 4,022 ₹ Cr in Q1 FY26 and 4,569 ₹ Cr in Q4 FY26. The company reported a revenue growth of 9% year-on-year (YoY).

Key profitability metrics included:

• EBITDA: 902 ₹ Cr, representing a 7% increase YoY from 846 ₹ Cr in Q1 FY26.
• Profit Before Tax (PBT): 141 ₹ Cr, marking a 24% growth compared to 114 ₹ Cr in Q1 FY26.
• Net Profit (Reported): 141 ₹ Cr, achieving a substantial 355% increase from 31 ₹ Cr reported in Q1 FY26.

Segment Performance Review​

Biosimilars
The Biosimilars segment reported a revenue of 2,855 ₹ Cr in Q1 FY27. This represented a 16% increase compared to 2,458 ₹ Cr in Q1 FY26 and an increase of 4% from 2,756 ₹ Cr recorded in Q4 FY26.

The segment generated an EBITDA of 728 ₹ Cr, which was up 10% YoY. The R&D spend for the Biosimilars segment was 192 ₹ Cr, achieving 7% of revenue from the operational expenditure side (as opposed to the overall company's reported 7%).

The growth in this segment is primarily attributed to the North America market. Biocon noted that recent US commercializations include Yesafili (bAflibercept), Bosaya & Aukelso (bDenosumab), and gLiraglutide. The company also mentioned the EMA approval for a second insulin drug product line in Malaysia, which is expected to double capacity and support future growth.


Generics
The Generics segment reported a revenue of 760 ₹ Cr in Q1 FY27, marking a 21% YoY increase from the 630 ₹ Cr recorded in Q1 FY26. The EBITDA for the segment was 56 ₹ Cr.

The financial performance is noted to be driven by margin improvement resulting from operating leverage and cost efficiency initiatives. Generic liraglutide was cited as a key driver across multiple markets, including the USA. R&D expenditure for Generics stood at 47 ₹ Cr, which is a 33% decrease compared to 70 ₹ Cr in Q1 FY26.


Services
The Services segment reported a revenue of 736 ₹ Cr in Q1 FY27, down from 875 ₹ Cr in Q1 FY26 and 1,037 ₹ Cr in Q4 FY26. The EBITDA for the segment was 116 ₹ Cr.

Performance in this area was impacted by lower offtake from a key biologics client and forex hedge losses. This decline was partly offset by cost optimization initiatives. Strategic collaborations with BRIC-THSTI were highlighted as enhancing translational research and clinical development capabilities.

Strategic Outlook and Positioning​

Biocon Limited noted that the next phase of growth is positioned through an integrated platform, global scale, and resilient supply networks. The company emphasized its market positioning in North America, citing policy tailwinds and affordability as central to the dialogue. Europe continues to benefit from a combined portfolio including 11 biosimilars and eight generic medicines.

The company’s strategy includes focusing on improving margins, free cash flow generation, and Return on Capital Employed (RoCE). The Generics profitability is noted to be showing early benefits of operating leverage and fiscal prudence.

BIOCON Stock Price Movement​

On Wednesday, shares of Biocon Limited edged higher to close at ₹425.20, gaining 0.76%. The stock traded a total of 3.30 million shares during the session.